KLOW: GLOW + KPV
The gut-focused variant: the GLOW trio plus the anti-inflammatory tripeptide.
Why this stack
KLOW is GLOW with KPV added. KPV is a three-amino-acid fragment of alpha-MSH studied for gut and skin inflammation, so the blend gets picked when the research question leans inflammatory: gut lining, irritated skin, or recovery with an inflammation component. Like GLOW it ships pre-mixed, and the blend protocol page carries the escalating schedule.
The protocol at a glance
Community-reported maintenance amounts, derived live from each compound's protocol page. Click through for titration phases, reconstitution steps and the evidence grading behind every number.
| Compound | Dose | Frequency | Recon | Units/injection |
|---|---|---|---|---|
| GHK-Cu Animal data only |
2 mg | Once daily, 5 days on / 2 off | 50 mg + 2.5 mL | 10 units (0.1 mL) |
| BPC-157 Animal data only |
600 mcg | Once daily | 10 mg + 1 mL | 6 units (0.06 mL) |
| TB-500 Animal data only |
1 mg | Once daily | 10 mg + 1 mL | 10 units (0.1 mL) |
| KPV Animal data only |
500 mcg | Once daily | 10 mg + 1 mL | 5 units (0.05 mL) |
How it is run
- Once daily subcutaneous as the pre-mixed blend, following the KLOW protocol page escalation.
- Separate-vial versions mirror the GLOW split, with KPV daily alongside.
- Blocks of 4 to 8 weeks with about 4 weeks off.
What the components report
Reported upsides
- GHK-Cu: Copper peptide supporting skin and tissue remodelling
- GHK-Cu: Stimulates collagen synthesis and wound healing
- BPC-157: Consistently accelerates healing in rodent injury models
- BPC-157: Anti-inflammatory and cytoprotective in preclinical work
- TB-500: Promotes cell migration and tissue repair in preclinical models
- TB-500: Anti-inflammatory properties reported in animal work
- KPV: Anti-inflammatory tripeptide from alpha-MSH
- KPV: Gut and skin inflammation focus in research
Cautions
- GHK-Cu: Injection site reactions
- GHK-Cu: Skin discolouration at injection site (copper)
- BPC-157: No human safety data from controlled trials
- BPC-157: Injection site reactions
- TB-500: No human clinical safety data
- TB-500: Injection site reactions possible
- KPV: Limited human data
- KPV: Injection site reactions
Pulled from each compound's benefits and side effects section. Individual responses vary. Not medical advice.
Track this stack
The free tracker logs each component on its own schedule, rotates injection sites across the whole stack, and counts down every vial with a reorder heads-up.
Sourcing the stack
Same rule as every protocol page: the batch COA matters more than the price. Summit Research Supply is the supplier we feature; code PEPDOSE applies to each component.
GHK-Cu →BPC-157 →TB-500 →KPV →
Summit links are affiliate links. Our COA checklist applies the same way to any vendor.
